-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Critical Comparison: LadRx (OTCMKTS:CYTR) Vs. Quince Therapeutics (NASDAQ:QNCX)
Critical Comparison: LadRx (OTCMKTS:CYTR) Vs. Quince Therapeutics (NASDAQ:QNCX)
LadRx (OTCMKTS:CYTR – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Analyst Ratings
This is a breakdown of current recommendations for LadRx and Quince Therapeutics, as provided by MarketBeat.com.
Get LadRx alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
LadRx | 0 | 0 | 0 | 0 | N/A |
Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares LadRx and Quince Therapeutics' top-line revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
Quince Therapeutics | N/A | N/A | -$89.94 million | ($2.23) | -0.31 |
Quince Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Profitability
This table compares LadRx and Quince Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
LadRx | N/A | -67.61% | -45.39% |
Quince Therapeutics | N/A | -63.19% | -58.43% |
Insider and Institutional Ownership
0.1% of LadRx shares are held by institutional investors. Comparatively, 25.8% of Quince Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 27.9% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
About LadRx
(Get Rating)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
About Quince Therapeutics
(Get Rating)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
LadRx (OTCMKTS:CYTR – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
LADRX (OTCMKTS: CYTR — 獲得評級) 和木瓜治療 (NASDAQ: QNCX — 獲得評級) 都是小型股醫療公司, 但這是優越的投資?我們將根據兩家企業的機構所有權,股息,風險,收益,盈利能力,分析師建議和估值的實力進行比較。
Analyst Ratings
分析師評級
This is a breakdown of current recommendations for LadRx and Quince Therapeutics, as provided by MarketBeat.com.
這是當前針對 LADRX 和木瓜治療法的建議的細分,由 MarketBeat.com 提供。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
LadRx | 0 | 0 | 0 | 0 | N/A |
Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
LADRX | 0 | 0 | 0 | 0 | N/A |
木瓜治療 | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
盈利及估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
Quince Therapeutics | N/A | N/A | -$89.94 million | ($2.23) | -0.31 |
總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
LADRX | N/A | N/A | -670 萬美元 | (0.15 美元) | N/A |
木瓜治療 | N/A | N/A | -8994 萬美元 | (二百二十三元) | -0.31 |
Quince Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
木瓜治療學的交易價格與收益率低於 LaDrX,這表明它目前在兩隻股票中價格更便宜。
Volatility & Risk
波動性和風險
LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
LADRX 的測試版為 1.96,表明其股價比標普 500 的波動性高 96%。相比之下,木瓜治療的測試值為 1.08,這表明其股價比標普 500 的波動性高 8%。
Profitability
盈利
This table compares LadRx and Quince Therapeutics' net margins, return on equity and return on assets.
此表格比較了 LaDRX 和木瓜治療的淨利潤率,股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
LadRx | N/A | -67.61% | -45.39% |
Quince Therapeutics | N/A | -63.19% | -58.43% |
淨利潤 | 權益回報率 | 資產回報率 | |
LADRX | N/A | -67.61% | -45.39% |
木瓜治療 | N/A | -63.19% | -58.43% |
Insider and Institutional Ownership
內幕和機構所有權
0.1% of LadRx shares are held by institutional investors. Comparatively, 25.8% of Quince Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 27.9% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
0.1% 的股票由機構投資者持有。相比之下,25.8% 的木瓜治療股份由機構投資者持有。12.8% 的 LADRX 股票由內部人士持有。相比之下,木瓜治療學股份的 27.9% 由內部人士持有。強大的機構所有權表明,大型資金經理,對沖基金和捐贈基金認為股票將在長期內優於市場。
About LadRx
關於我們
(Get Rating)
(取得評分)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LADRX Corporation 是一家生物製藥公司,致力於治療癌症患者的治療藥物的發現和開發。該公司的先進藥物共軛,阿多柔比星是在後期臨床試驗中是抗癌藥物多柔比星的一個版本。其臨床前治療包括鏈接器活性藥物釋放 7、8、9 和 10 針對癌症。該公司以前稱為 CyTRX 公司,並於 2022 年 9 月更名為 LADRX 公司。LADRX 公司成立於 1985 年,總部位於加利福尼亞州洛杉磯。
About Quince Therapeutics
關於木瓜治療
(Get Rating)
(取得評分)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
木瓜治療,Inc. 是一家生物製藥公司,致力於推進針對衰弱和罕見疾病的精密治療。該公司發現了一個廣泛的骨靶向藥物平台,可以將小分子,肽或大分子直接精確地輸送到骨折和疾病部位。它的鉛化合物是 NOV004,這是一種合成代謝肽,旨在精確定位並集中在骨折部位。該公司以前稱為 Cortexyme,Inc.,並於 2022 年 8 月更名為木瓜治療藥公司。木瓜治療有限公司成立於 2012 年,總部位於加利福尼亞州南舊金山。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 LaDrX 每日的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收對 LADRX 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧